Phase 2, Double-blind, Randomized, Placebo-Controlled Study to Evaluate Safety and Efficacy of H56:IC31 in Reducing the Rate of TB Disease Recurrence in HIV Negative Adults Successfully Treated for Drug-Susceptible Pulmonary Tuberculosis
Phase of Trial: Phase II
Latest Information Update: 14 Feb 2019
At a glance
- Drugs H56IC (Primary)
- Indications Pulmonary tuberculosis
- Focus Proof of concept; Therapeutic Use
- Sponsors Aeras
- 05 Feb 2019 Planned End Date changed from 30 Dec 2020 to 31 Dec 2022.
- 05 Feb 2019 Planned primary completion date changed from 30 Sep 2020 to 6 Apr 2022.
- 05 Feb 2019 Status changed from not yet recruiting to recruiting.